LAMTOR5 and breast carcinoma: In 2017, Wang et al. (2017) found that oncoprotein hepatitis B X-interacting protein (HBXIP) is able to up-regulate ACSL1 (long-chain fatty acyl-CoA synthetase 1) by activating transcriptional factor Sp1 in breast cancer.